International cohort study of colorectal cancer patients
ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis
This study is trying to learn more about colorectal cancer by following patients from their first diagnosis for up to five years to see how they respond to treatment and what factors might affect their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | University of Utah Academic / other |
| Locations | 7 sites (Los Angeles, California and 6 other locations) |
| Trial ID | NCT02328677 on ClinicalTrials.gov |
What this trial studies
The ColoCare Study is a multicenter, international prospective cohort initiative focused on patients diagnosed with stage I-IV colorectal cancer. It aims to establish a comprehensive database of clinical outcomes, including disease-free and overall survival, predictors of cancer recurrence, and treatment toxicities. Patients aged 18-89 years are recruited at the time of their first diagnosis and followed for up to five years, with regular assessments and specimen collection. The study also includes cross-sectional analyses of biomarkers and health behaviors to better understand the disease.
Who should consider this trial
Good fit: Ideal candidates for this study are newly diagnosed colorectal cancer patients aged 18-89 years.
Not a fit: Patients who do not meet the age criteria or those who are unable to consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into colorectal cancer prognosis and improve patient outcomes through tailored treatment strategies.
How similar studies have performed: Other studies have shown success with similar cohort approaches in understanding cancer outcomes, making this a promising initiative.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-89 years; for patients recruited after 09/01/2021 the age range is 18-69 years. Recruitment of patients 70 years and older was maintained for specific sub-studies and re-initiated for specific R01 grant funding in \~06/2024 2. Men and women 3. Newly-diagnosed colon or rectal cancer (stages I-IV); CRC in treatment (FHCRC and HCI) 4. English (FHCRC, Moffitt, HCI, Cedars-Sinai, WashU St. Louis) or German (University Hospital Heidelberg)-speaking; 5. mentally/physically able to consent and participate. Exclusion Criteria: * if one of the above in not fulfilled * insufficient language or consent capacity
Where this trial is running
Los Angeles, California and 6 other locations
- Cedars-Sinai Medical Center — Los Angeles, California, United States (Recruiting)
- Lee H. Moffitt Cancer Center — Tampa, Florida, United States (Recruiting)
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
- University of Tennessee — Knoxville, Tennessee, United States (Recruiting)
- Huntsman Cancer Institute — Salt Lake City, Utah, United States (Recruiting)
- Fhcrc — Seattle, Washington, United States (Recruiting)
- University Hospital Heidelberg — Heidelberg, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Principal investigator: Cornelia M Ulrich, MS, PhD — Huntsman Cancer Institute
- Study coordinator: Cornelia Ulrich, MS, PhD
- Email: neli.ulrich@hci.utah.edu
- Phone: (801) 213-5716
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.